HC Wainwright Issues Optimistic Estimate for CGTX Earnings

by · The Markets Daily

Cognition Therapeutics, Inc. (NASDAQ:CGTX – Free Report) – Equities research analysts at HC Wainwright boosted their Q3 2026 EPS estimates for Cognition Therapeutics in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.06) per share for the quarter, up from their prior estimate of ($0.07). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q4 2026 earnings at ($0.05) EPS and FY2026 earnings at ($0.20) EPS.

Several other research analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a report on Wednesday, June 24th. Wall Street Zen cut Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Cognition Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $3.33.

Read Our Latest Analysis on CGTX

Cognition Therapeutics Stock Down 3.7%

NASDAQ CGTX opened at $0.98 on Monday. The company has a market capitalization of $93.37 million, a P/E ratio of -5.78 and a beta of 1.78. Cognition Therapeutics has a 12-month low of $0.55 and a 12-month high of $3.83. The firm has a 50-day moving average price of $1.09 and a two-hundred day moving average price of $1.10.

Cognition Therapeutics (NASDAQ:CGTX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of CGTX. Northwestern Mutual Wealth Management Co. increased its holdings in Cognition Therapeutics by 11,695.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,060,282 shares of the company’s stock valued at $2,781,000 after buying an additional 2,042,815 shares during the period. Sigma Planning Corp raised its position in shares of Cognition Therapeutics by 70.1% in the 4th quarter. Sigma Planning Corp now owns 216,165 shares of the company’s stock valued at $295,000 after buying an additional 89,075 shares in the last quarter. CM Management LLC bought a new stake in shares of Cognition Therapeutics during the 4th quarter worth approximately $270,000. Tocqueville Asset Management L.P. acquired a new stake in shares of Cognition Therapeutics during the 2nd quarter worth approximately $369,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Cognition Therapeutics during the 2nd quarter worth approximately $165,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

(Get Free Report)

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.

Recommended Stories